

Pharmacology of TTX-resistant and TTX-sensitive sodium currents in non-human primate dorsal root ganglion sensory neurons

Dong Liu, Chen Tian, Adina Hazan, Mahsa Sadeghi, Christian Petroski, Robert Petroski
Neuroservices-Alliance (Neuroservice USA - in vitro cell electrophysiology)



Background

Chronic pain is poorly managed by current therapies. The opiate epidemic has highlighted the need for alternative therapies for treating pain. Genetic and functional studies have established an important role of voltage-gated sodium channels in human pain disorders. Tetrodotoxin-sensitive (TTX-S) and tetrodotoxin-resistant (TTX-R) sodium channels expressed in dorsal root ganglion (DRG) sensory neurons are currently being pursued as promising therapeutic targets for treating human pain. Many drug discovery programs rely on pharmacology data from rodent neurons for generating the structure-activity relationships (SAR) during lead optimization. However, the pharmacological activity of compounds on rodent target proteins sometimes differs from their human orthologs and poses a challenge for identifying the best pre-clinical candidates to advance to human clinical trials. Here we describe the development and validation of an electrophysiological assay of TTX-R sodium channels from non-human primate (NHP) and dog DRG sensory neurons and show the efficacy and potency of 14 compounds for blocking TTX-R sodium currents. These results reveal differences in compound activity on native sodium channels from different species.

Methods

DRGs were harvested from adult cynomolgus monkeys and dogs. The animals were humanely euthanized in an AAALAC accredited facility using an IACUC approved protocol to minimize pain and suffering. The tissue was dissociated using enzymatic and mechanical methods and sensory neurons were plated on poly-D-lysine and laminin coated glass coverslips in Neurobasal/B27 medium supplemented with NGF (25 ng/ml). Whole cell patch clamp recordings were conducted at 1, 2, and 3 days *in vitro*. The composition of the external recording solution was: 110 mM choline-Cl, 30 mM NaCl, 2.5 mM KCl, 2 mM CaCl₂, 1.3 mM MgCl₂, 10 mM glucose, 10 mM HEPES pH 7.3. The composition of the internal recording solution was: 70 mM CsCl, 70 mM CsF, 3 mM MgCl₂, 5 mM EGTA, 0.5 mM CaCl₂, 4 mM Na₂-ATP, 0.3 mM Li-GTP, 10 mM HEPES pH 7.3. Upon establishing the whole cell configuration, we measured the passive membrane properties for every cell (Cm, Rm, Ra). TTX-resistant sodium currents were measured in the presence of 0.5 μ M TTX.

TTX-R Na currents





Figure 1. Photomicrographs and representative Na current traces from NHP, dog and mouse DRG neurons. TTX-resistant currents shown in red.

Passive properties and TTX-R fraction



	NHP	Dog	Mouse	
Capacitance	95.9 \pm 2.9 pF (n=326)	92.2 \pm 3.8 pF (n=132)	34.7 \pm 1.8 pF (n=57)	
Resistance	303.3 \pm 15.6 M Ω (n=326)	341.5 \pm 38.6 M Ω (n=131)	557.6 \pm 65.0 M Ω (n=60)	
Diameter	35.9 \pm 6.0 μ m (n=94)	39.4 \pm 12.9 μ m (n=55)	23.4 \pm 3.6 μ m (n=71)	
TTX-R %	1 div	73 \pm 2 % (n=89)	70 \pm 4 % (n=50)	54 \pm 8 % (n=25)
	2 div	81 \pm 3 % (n=81)	66 \pm 5 % (n=31)	39 \pm 5 % (n=32)
	3 div	81 \pm 4 % (n=51)	53 \pm 8 % (n=7)	26 \pm 4 % (n=32)

Figure 2. NHP and dog DRG neurons exhibited similar properties including capacitance, membrane resistance, and diameter. Conversely, mouse DRG neurons were smaller, had a lower capacitance and higher resistance. The proportion of TTX-R current did not decrease over 3 days *in vitro* in NHP or dog DRG neurons. In contrast, the proportion of TTX-R current decreased significantly in mouse DRG neurons.

Voltage-dependent activation and inactivation






Figure 3. NHP and dog DRG neurons exhibited similar voltage-dependent activation (A) and inactivation (B) properties of TTX-R Na currents.

Concentration-response of 14 compounds on TTX-R Na currents




Drug 06




	NHP	Dog
E_{max} (% block)	100%	<50% at 10 μ M
IC₅₀	121 nM	>10 μ M
Slope	0.80	n.a.

Drug 07




	NHP	Dog
E_{max} (% block)	100%	<50% at 10 μ M
IC₅₀	39 nM	>10 μ M
Slope	0.68	n.a.

Drug 08




	NHP	Dog
E_{max} (% block)	100%	<50% at 10 μ M
IC₅₀	31 nM	>10 μ M
Slope	0.90	n.a.

Drug 09




	NHP
E_{max} (% block)	100%
IC₅₀	281 nM
Slope	0.88

Drug 10




	NHP
E_{max} (% block)	100%
IC₅₀	121 nM
Slope	0.93

Drug 11




	NHP
E_{max} (% block)	100%
IC₅₀	60 nM
Slope	0.50

Drug 12




	NHP
E_{max} (% block)	100%
IC₅₀	326 nM
Slope	0.75

Drug 13



	NHP
E_{max} (% block)	100%
IC₅₀	239 nM
Slope	0.84

Drug 14



	NHP
E_{max} (% block)	100%
IC₅₀	176 nM
Slope	0.72

Figure 4. All compounds completely blocked TTX-R Na currents in NHP DRG neurons (black). 8 of the compounds that were also tested in dog DRG neurons did not exhibit block (blue).

Conclusions

- We developed and validated an electrophysiological assay of native TTX-resistant Na currents from sensory neurons isolated from non-human primate and dog dorsal root ganglia.
- Nav1.8 antagonists potently and completely blocked TTX-R in NHP but not dog sensory neurons.